Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) in a research note issued to investors on Tuesday morning, MarketBeat.com reports. The firm issued an overweight rating on the biotechnology company’s stock.
Several other equities analysts have also issued reports on the stock. Jefferies Financial Group raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and boosted their price target for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. Piper Sandler raised shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $3.00 to $13.00 in a report on Monday, November 18th. Leerink Partnrs raised shares of Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 19th. BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 target price for the company in a research note on Tuesday, November 19th. Finally, StockNews.com lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 8th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Aclaris Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.
Check Out Our Latest Analysis on ACRS
Aclaris Therapeutics Stock Performance
Hedge Funds Weigh In On Aclaris Therapeutics
Large investors have recently modified their holdings of the business. ExodusPoint Capital Management LP acquired a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $26,000. Invesco Ltd. acquired a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $28,000. Graham Capital Management L.P. acquired a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $35,000. Commonwealth Equity Services LLC acquired a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $36,000. Finally, Alpine Global Management LLC acquired a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $38,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Recommended Stories
- Five stocks we like better than Aclaris Therapeutics
- What Investors Need to Know to Beat the Market
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Trading Halts Explained
- 3 Must-Own Stocks to Build Wealth This Decade
- What Are Dividend Champions? How to Invest in the Champions
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.